The biotechnology industry is at the forefront of some of the most pivotal discoveries in human history…
Companies operating in the space develop treatments for diseases ranging from diabetes to cancer. These same firms are also the ones behind game-changing vaccine technologies like we’ve seen with Pfizer (PFE) and Moderna (MRNA).
But just because COVID-19 vaccines have held much of the limelight in the industry over the past year, it doesn’t mean other groundbreaking treatments haven’t been approved in recent weeks…
Yet, with the world slowly returning to some semblance of “normal,” many investors have shifted their attention away from the sector to more cyclical stocks.
In turn, major drug approvals are being overlooked now more than ever.
That’s exactly why we’re bringing you biotech stocks with major long-term catalysts for future share growth…
MindMed (MNMD) is a psychedelic medicine and therapy developer.
The company is working to cure depression, fight alcoholism, and help individuals break their addictions to other, more dangerous, medications on the market, in response to the surge in mental health concerns and the growing awareness surrounding them.
Psychedelics have the ability to treat those suffering from serious diseases including Alzheimer's and schizophrenia, according to published research and studies.
The company is making great progress in developing psychedelic therapies for therapeutic usage, with more ongoing trials than any other biotech company in the field. It is now conducting multiple Phase I and Phase II trials.
There hasn't been a psychedelic treatment that has made it to Phase III yet. This indicates that if MNMD makes a breakthrough, the stock's value might skyrocket in the future years.
Still, with MNMD trading as a penny stock on the Nasdaq, there are risks to investing in the company. But with those risks, come massive potential gains.
This Stock Is Developing Surveillance Solutions For Heart Transplant Patients
CareDx Inc. (NASDAQ: CDNA) is a healthcare services company that focuses in heart and kidney transplant surveillance systems.
CDNA reported $0.01 in earnings per share in the first quarter, compared to a $0.12 loss per share projected.
The company's earnings before interest, taxes, depreciation, and amortization (EBITDA) were $7.7 million, compared to a loss of $600,000 predicted by Wall Street.
The company's sales for the quarter was $67.4 million, compared to $61 million projected. And CDNA forecasts the positive momentum will continue thanks to the demand for its AlloSure and AlloMap offerings.
This prompted the company to enhance its full-year revenue forecast for 2021, to $270 million to $280 million, up from its earlier estimate of $255 million to $265 million.
Last week, shares of CDNA soared 8%…
With a market valuation of $4.5 billion, CDNA is more of a hidden treasure in the field, with lots of room to expand its revenue even higher.
The Alzheimer's Association estimates that, “caring for individuals with Alzheimer's will cost American society $20 trillion.”
Jim Cramer says a drug that could treat the disease “would be the biggest drug ever.”
The Wall Street Journal says the “financial benefits would be massive.”
One small biotech holds the key to a revolution in treating this dreaded disease.
Jeff Bezos, Goldman Sachs & a Big Pharma giant have invested billions into this unknown biotech.
And our research shows that anyone who gets in today could turn every $1,000 into $1.1 million.